Niklas Czeloth
Expert Panel at Boehringer Ingelheim
Frankfurt Rhine-Main Metropolitan Area
Overview
Work Experience
Chairman of the Board (Interim)
2023 - Current
Director Board of Directors
2023
Chairman of the Board (Interim)
2023
Director Board of Directors
2023
Member of Boehringer Ingelheim´s Immunogenicity Expert Panel
2014
Executive Director / Investment Manager - Boehringer Ingelheim Venture Fund
2020
Interest in early investment opportunities in immuno-oncology, regenerative medicine and anti-infectives. (Please describe scope of interaction in contact requests. Thank you!)
International Project Leader (Oncology, Retinopathy, CNS projects)
2018 - 2020
Project leadership for global drug development projects
Director / Head of Biosciences (Nonclinical / DMPK / Pharmacology) Biosimilars
2014 - 2018
Head of Bioanalysis/DMPK Biosimilar Programs Heading of non-clinical activities for Biosimilars Portfolio Serving as Head of Nonclinical for Biosimilar projects Pharmacology / Toxicology activities for the Biosimilars Business
Project Manager DMPK Biosimilars
2013 - 2014
Pharmacokinetics of monoclonal antibodies (biosimilarity trials, population PK) Responsibility for Bionalysis/DMPK (PK, ADA, nAb assays) Pharmacology of monoclonal antibodies (SPR, CDC, ADCC, effector functions, FcR, glycosylation) Immunogenicity Toxicological studies Translational research/devlopment Regulatory agenciy interactions
Director Board of Directors
2020 - 2021
Leiter Pharmakologie Biotherapeutika
2008 - 2013
Associate Director Pharmacology Biotherapeutics. Expertise Preclinical Development, Immunology, ICH Guidelines, IMPD/IND preparation, Toxicology, PK/PD, Project management, Monoclonal Antibodies, Biotherapeutics, Flowcytometrie, Research Tregs, Collaboration Management.
Scientist
2003 - 2007
Scientist Immunology Basic Research Dendritic cells, T cells, Tregs, B cells, Cell Trafficking, S1P signalling. Expertise FACS, cell sorting, Immunofluorescence, Antibody production, labelling.basic immunology, RT-PCR.